Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform an

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the

Haemonetics (HAE) was a big mover last session on higher-than-average trading volume. The latest tre

On October 08, 2026, Haemonetics Corp (HAE) shares experienced a significant rise of 17.5%, bringing

ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma

BTIG analyst Marie Thibault maintains Haemonetics (NYSE:HAE) with a Buy and raises the price targ

Gainers Pacira BioSciences (NASDAQ:PCRX) shares moved upwards by 44.0% to $36.3 during Thursday&#39

Haemonetics stock hits a new 52-week high after CSL Plasma outlines a sweeping rollout of its techno

Haemonetics (NYSE:HAE) shares jumped over 13% to $115.20 on Thursday after CSL set out a timetable f

CSL Plasma plans to use Haemonetics' plasma collection equipment across all existing U.S. centers, e

U.S. stocks fell, while Helen of Troy jumped 15.5% on strong earnings and raised guidance. Pacira so

Gainers Profound Medical (NASDAQ:PROF) shares moved upwards by 21.5% to $6.9 during Thursday's

Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal H

Haemonetics (NYSE:HAE) released first-quarter financial results and hosted an earnings call on Thurs

Findings highlight opportunities for further improvement in treatment use and adherence, despite the

BOSTON, Sept. 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Compan

Femasys (NASDAQ: FEMY - Get Free Report) and Haemonetics (NYSE: HAE - Get Free Report) are both heal

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

Intellia Therapeutics NASDAQ: NTLA executives outlined plans for a potential launch of its hereditar

Investors interested in stocks from the Medical - Products sector have probably already heard of Phi

Analysts upgraded SUNB, HAWK, and more, revising ratings and price targets.

Citigroup analyst Joanne Wuensch upgrades Haemonetics (NYSE:HAE) from Neutral to Buy and raises t

Payment follows approximately $5 million received in January 2026, bringing total cash proceeds rece

NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency

FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027 Positions lonvo-z to be the w

ZUG, Switzerland, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharm

Raymond James analyst Andrew Cooper maintains Haemonetics (NYSE:HAE) with a Outperform and raises

Investors with an interest in Medical - Products stocks have likely encountered both GE HealthCare T

BioCryst Pharmaceuticals (BCRX) is evolving into a dual-product hereditary angioedema (HAE) franchis

— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation,

Top Wall Street analysts changed outlook on top names. Baird raised PSN target, BTIG cut WMT target,

Baird analyst David Rescott maintains Haemonetics (NYSE:HAE) with a Outperform and raises the pri

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform an

Shares of Haemonetics Corp (NYSE: HAE) are trading higher Tuesday afternoon following news of a sign

US stocks down, Nasdaq falls 300+ points. Duos Tech shares rise on better Q2 results. Many other bi

BTIG analyst Marie Thibault maintains Haemonetics (NYSE:HAE) with a Buy and raises the price targ

Gainers Amylyx Pharmaceuticals (NASDAQ:AMLX) stock increased by 27.5% to $27.32 during Tuesday'

Haemonetics anticipates CSL to transition a portion of its U.S. plasma collection centers to the Com

Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Neutral and raises the p

JP Morgan analyst Allen Gong maintains Haemonetics (NYSE:HAE) with a Neutral and raises the price

BTIG analyst Marie Thibault maintains Haemonetics (NYSE:HAE) with a Buy and raises the price targ

Haemonetics (NYSE:HAE) widens FY2027 sales outlook from $1.410 billion-$1.427 billion to $1.401 bill

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the

Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Neutral and raises the p

Analysts upgraded HAE, VIK, and TXN, and raised price targets. Check out other analysts' views o

B of A Securities analyst Craig Bijou upgrades Haemonetics (NYSE:HAE) from Neutral to Buy and rai

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform an

JP Morgan analyst Allen Gong maintains Haemonetics (NYSE:HAE) with a Neutral and lowers the price